Type 2 NADH dehydrogenase is the only point of entry for electrons into the Streptococcus agalactiae respiratory chain and is a potential drug target

Lencina, Andrea M., Franza, Thierry, Sullivan, Matthew J. ORCID: https://orcid.org/0000-0003-2276-3132, Ulett, Glen C., Ipe, Deepak S., Gaudu, Philippe, Gennis, Robert B. and Schurig-Briccio, Lici A. (2022) Type 2 NADH dehydrogenase is the only point of entry for electrons into the Streptococcus agalactiae respiratory chain and is a potential drug target. mBIO, 9 (4). ISSN 2161-2129

[thumbnail of mBio.01034-18]
PDF (mBio.01034-18) - Published Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview


The opportunistic pathogen Streptococcus agalactiae is the major cause of meningitis and sepsis in a newborn’s first week, as well as a considerable cause of pneumonia, urinary tract infections, and sepsis in immunocompromised adults. This pathogen respires aerobically if heme and quinone are available in the environment, and a functional respiratory chain is required for full virulence. Remarkably, it is shown here that the entire respiratory chain of S. agalactiae consists of only two enzymes, a type 2 NADH dehydrogenase (NDH-2) and a cytochrome bd oxygen reductase. There are no respiratory dehydrogenases other than NDH-2 to feed electrons into the respiratory chain, and there is only one respiratory oxygen reductase to reduce oxygen to water. Although S. agalactiae grows well in vitro by fermentative metabolism, it is shown here that the absence of NDH-2 results in attenuated virulence, as observed by reduced colonization in heart and kidney in a mouse model of systemic infection. The lack of NDH-2 in mammalian mitochondria and its important role for virulence suggest this enzyme may be a potential drug target. For this reason, in this study, S. agalactiae NDH-2 was purified and biochemically characterized, and the isolated enzyme was used to screen for inhibitors from libraries of FDA-approved drugs. Zafirlukast was identified to successfully inhibit both NDH-2 activity and aerobic respiration in intact cells. This compound may be useful as a laboratory tool to inhibit respiration in S. agalactiae and, since it has few side effects, it might be considered a lead compound for therapeutics development. IMPORTANCE S. agalactiae is part of the human intestinal microbiota and is present in the vagina of ~30% of healthy women. Although a commensal, it is also the leading cause of septicemia and meningitis in neonates and immunocompromised adults. This organism can aerobically respire, but only using external sources of heme and quinone, required to have a functional electron transport chain. Although bacteria usually have a branched respiratory chain with multiple dehydrogenases and terminal oxygen reductases, here we establish that S. agalactiae utilizes only one type 2 NADH dehydrogenase (NDH-2) and one cytochrome bd oxygen reductase to perform respiration. NADH-dependent respiration plays a critical role in the pathogen in maintaining NADH/NAD+ redox balance in the cell, optimizing ATP production, and tolerating oxygen. In summary, we demonstrate the essential role of NDH-2 in respiration and its contribution to S. agalactiae virulence and propose it as a potential drug target.

Item Type: Article
Additional Information: Funding Information: This work was supported by grants from the United States National Institutes of Health GM095600 and HL16101 (R.B.G.) and grants from the Australia National Health and Medical Research Council APP1146569 and APP1146820 (G.C.U.).
Uncontrolled Keywords: bacterial pathogenesis,drug discovery,electron transport chain,nadh dehydrogenase,streptococcus agalactiae,microbiology,virology,sdg 3 - good health and well-being ,/dk/atira/pure/subjectarea/asjc/2400/2404
Related URLs:
Depositing User: LivePure Connector
Date Deposited: 15 Aug 2022 10:31
Last Modified: 23 Oct 2022 21:32
URI: https://ueaeprints.uea.ac.uk/id/eprint/87244
DOI: 10.1128/mBio.01034-18


Downloads per month over past year

Actions (login required)

View Item View Item